Knowledge Hub

Welcome to the May 2026 edition of the 360 Clinical Research Consultancy Insights! In this issue, FDA Inspection Reach, Real-Time Trials, and Modern Evidence Design.

Welcome to the April 2026 edition of the 360 Clinical Research Consultancy Insights! In this issue, The New UK Clinical Trials Regulations Are Live: What April 2026 Changed in Practice

Welcome to the March 2026 edition of the 360 Clinical Research Consultancy Insights! In this issue, March Becomes the Implementation Month: What the UK’s Countdown Webinar Revealed

Welcome to the February 2026 edition of the 360 Clinical Research Consultancy Insights! In this issue, FDA’s One-Trial Default Changes the Conversation: What February 2026 Means for Drug Development Strategy.

Welcome to the January 2026 edition of the 360 Clinical Research Consultancy Insights! In this issue, UK Clinical Trial Competitiveness Becomes a 2026 Priority: Faster Assessments, Agile Regulation, and What It Means for Sponsors

Welcome to the December 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, Year-end review and 2026 outlook for clinical research.

Welcome to the November 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, Clinical trial diversity and inclusion initiatives.

Welcome to the October 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, EU regulatory updates and clinical trial transparency trends.

Welcome to the September 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, FDA updates including E6(R3) finalisation and adaptive design guidance.

A sponsor company running a suite of early access programs discovered critical gaps in oversight, safety reporting, and HCP accountability — prompting a structured audit-led intervention.

Welcome to the August 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, Portfolio strategy and selectivity in development pipelines.

Welcome to the July 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, Midyear productivity and operational performance focus.

Welcome to the June 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, Biopharma dealmaking trends and UK transitional guidance.

Welcome to the May 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, AI Hype Meets Site Reality: Why Adoption Still Looks Uneven in Clinical Research

A start-up biotech company developing an innovative investigational drug product faced growing challenges around oversight, data integrity, and inspection readiness as it moved into later phase development.

Welcome to the April 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, UK Clinical Trial Reform Moves From Proposal to Reality

Welcome to the March 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, The EU’s New Clinical Trial Map Could Change How Patients Find Studies

Welcome to the February 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, ACT EU workshop focused on implementing ICH E6(R3) and modernizing GCP.

Welcome to the January 2025 edition of the 360 Clinical Research Consultancy Insights! In this issue, we delve into the latest trends and insights in healthcare audits, compliance, and risk management.